GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing ...

GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal ...

GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour. In a new white paper from the World Without Disease ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for GSK5764227, GSK’227, ...

Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff ...

Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.86% to 8,280.36.

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025 ...